Over the past 20 years, targeted inhibitors of both the ALK and EGFR oncogene have been successfully developed and approved for use in patients with non-small cell lung cancer (NSCLC) testing positive for these oncogenes [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.